// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Looking at factors which put MSM at higher risk of Hepatitis C acquisition

Sarah Smith - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

N/A

Introduction of online resources as an alternative to pre-insertion counselling for intrauterine contraception (IUC): A service evaluation

Andrew J Motherwell - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

An analysis of sexual assault presentations, reporting and engagement in follow-up care in a specialist level-3 service

Aaron Chady - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Infections diagnosed in female sex workers attending an inner city sexual health clinic

Michelle Pearson - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Managing chlamydia contacts: should clinics implement a test and wait process as recommended for gonorrhoea and does patient age make a difference?

Beth Hamer - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

HIV risks in the transgender Hijra community of the Indian subcontinent (specifically India and Pakistan), and potential prevention methods

Saif Abbas Chatoo - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Facilitators and barriers to Pre-Exposure Prophylaxis (PrEP) acceptability among ethnic minority men-who-have-sex-with-men (EMMSM): a systematic review

Adrian McGrath - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Sexually transmitted infection (STI) research priority setting – working with patients, the public, clinicians and stakeholders to identify STI research priorities for the North West of England

Hannah Browne - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

How long does it take to make an appointment at a sexual health clinic in the UK?

Tessa Mitchell - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Access to sexual health clinics in the UK; a mystery shopping telephone service evaluation

Annabel Gerard-Pearse - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Genital herpes

N/A

Gonorrhoea culture in a hub and spoke service

Charlotte Cossey - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A critical review of NICE guideline’s recommendation to provide empirical antibiotic therapy for those suspected to have chlamydia trachomatis and their partners

Megan Prince - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Lymphogranuloma venereum in a heterosexual male

Soonita Oomeer - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Flopen

Antimicrobial resistance in the management of Mycoplasma genitalium

Eleanor Haslegrave - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Moxifloxacin

Keeping an eye on syphilis

Elizabeth Nicol - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Could the introduction of a test and wait policy for the management of chlamydia contacts result in significant treatment delays and clinical complications for patients?

Rachel Frackelton - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Mycoplasma genitalium testing for patients with persistent non-gonococcal urethritis and pelvic inflammatory disease- an evaluation of treatment outcomes

Natalia Sterling - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Analysis of chlamydia and gonorrhoea co-infection in those with presumptive gonorrhoea diagnosed via same-day microscopy. A retrospective case note review

Stephanie Rashbrook - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

12 years of continuous audit of neisseria gonorrhoeae (GC): comparing management at an Integrated Sexual Health Service (ISHS) to national guidelines

Rebecca Cannon - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Neisseria gonorrhoeae (GC) – a worrying trend in antibiotic resistance from 2007 to 2019

Rebecca Cannon - British Association for Sexual Health and HIV (BASHH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved